Senti Biosciences (SNTI) Expected to Announce Earnings on Tuesday

Senti Biosciences (NASDAQ:SNTI - Get Free Report) is anticipated to issue its Q1 2025 earnings data before the market opens on Tuesday, May 6th. Analysts expect the company to announce earnings of ($0.56) per share and revenue of $1.30 million for the quarter.

Senti Biosciences (NASDAQ:SNTI - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The company reported ($1.41) earnings per share for the quarter, missing the consensus estimate of ($0.56) by ($0.85). The company had revenue of $1.30 million for the quarter, compared to analyst estimates of $1.30 million. On average, analysts expect Senti Biosciences to post $-15 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Senti Biosciences Price Performance

Shares of SNTI stock traded down $0.01 during trading hours on Thursday, reaching $3.31. The company had a trading volume of 46,552 shares, compared to its average volume of 801,622. Senti Biosciences has a 1-year low of $1.52 and a 1-year high of $16.94. The company has a 50 day moving average of $3.46 and a 200 day moving average of $3.66. The firm has a market cap of $86.30 million, a price-to-earnings ratio of -0.21 and a beta of 2.31.

Analyst Ratings Changes

Separately, Chardan Capital reiterated a "buy" rating and set a $12.00 target price on shares of Senti Biosciences in a report on Friday, May 2nd.

About Senti Biosciences

Senti Biosciences, Inc operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications.